BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38418394)

  • 21. The implication of lncRNA expression pattern and potential function of lncRNA RP4-576H24.2 in acute myeloid leukemia.
    Zheng J; Song Y; Li Z; Tang A; Fei Y; He W
    Cancer Med; 2019 Dec; 8(17):7143-7160. PubMed ID: 31568697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
    Lamble AJ; Kosaka Y; Laderas T; Maffit A; Kaempf A; Brady LK; Wang W; Long N; Saultz JN; Mori M; Soong D; LeFave CV; Huang F; Adams H; Loriaux MM; Tognon CE; Lo P; Tyner JW; Fan G; McWeeney SK; Druker BJ; Lind EF
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14331-14341. PubMed ID: 32513686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.
    van Galen P; Hovestadt V; Wadsworth Ii MH; Hughes TK; Griffin GK; Battaglia S; Verga JA; Stephansky J; Pastika TJ; Lombardi Story J; Pinkus GS; Pozdnyakova O; Galinsky I; Stone RM; Graubert TA; Shalek AK; Aster JC; Lane AA; Bernstein BE
    Cell; 2019 Mar; 176(6):1265-1281.e24. PubMed ID: 30827681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.
    Çelik H; Lindblad KE; Popescu B; Gui G; Goswami M; Valdez J; DeStefano C; Lai C; Thompson J; Ghannam JY; Fantoni G; Biancotto A; Candia J; Cheung F; Sukumar G; Dalgard CL; Smith RH; Larochelle A; Dillon LW; Hourigan CS
    Blood Adv; 2020 Jan; 4(2):367-379. PubMed ID: 31985806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
    Rutella S; Vadakekolathu J; Mazziotta F; Reeder S; Yau TO; Mukhopadhyay R; Dickins B; Altmann H; Kramer M; Knaus HA; Blazar BR; Radojcic V; Zeidner JF; Arruda A; Wang B; Abbas HA; Minden MD; Tasian SK; Bornhäuser M; Gojo I; Luznik L
    J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36099049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy.
    Kim D; Kim S; Song H; Gwak D; Min S; Byun JM; Koh Y; Hong J; Yoon SS; Yun H; Shin DY
    Cancer Med; 2024 Apr; 13(7):e7182. PubMed ID: 38591109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
    Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
    Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.
    Li Z; Liu X; Wang L; Zhao H; Wang S; Yu G; Wu D; Chu J; Han J
    Front Immunol; 2023; 14():1281687. PubMed ID: 38022588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.
    Grimm J; Simnica D; Jäkel N; Paschold L; Willscher E; Schulze S; Dierks C; Al-Ali HK; Binder M
    Blood Cancer J; 2022 Jan; 12(1):19. PubMed ID: 35091554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
    Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
    J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches.
    Li R; Xue K; Li J
    Front Med; 2022 Dec; 16(6):896-908. PubMed ID: 36053411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape of T Cells in NK-AML(M4/M5) Revealed by Single-Cell Sequencing.
    Wu W; Liang X; Li H; Huang X; Wan C; Xie Q; Liu Z
    J Leukoc Biol; 2022 Oct; 112(4):745-758. PubMed ID: 35258858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.
    Kelm RJ; Lamba GS; Levis JE; Holmes CE
    J Cell Biochem; 2018 Feb; 119(2):2073-2083. PubMed ID: 28834593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells.
    Pizzo RJ; Azadniv M; Guo N; Acklin J; Lacagnina K; Coppage M; Liesveld JL
    Exp Hematol; 2016 May; 44(5):378-89. PubMed ID: 26851308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.
    Sun YX; Kong HL; Liu CF; Yu S; Tian T; Ma DX; Ji CY
    Hum Immunol; 2014 Feb; 75(2):113-8. PubMed ID: 24269703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
    Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
    Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis.
    Wang J; Dao FT; Yang L; Qin YZ
    Sci Rep; 2020 Nov; 10(1):19037. PubMed ID: 33149230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.